DOI QR코드

DOI QR Code

Survival Outcome of AML Patients with and without TKD Mutations

  • Shahab, Sadaf (Department of Molecular Genetics, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Nisa, Khaleeq Un (Department of Molecular Genetics, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Nadeem, Muhammad (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Zahid, Danish (Department of Molecular Genetics, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Ansari, Saqib (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Farzana, Tasneem (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Taj, Mehwesh (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Borhany, Munira (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Ahmed, Nuzhat (Department of Molecular Genetics, NIBD Postgraduate Institute of Life Sciences Karachi) ;
  • Shamsi, Tahir S. (Department of Hematology, NIBD Postgraduate Institute of Life Sciences Karachi)
  • 발행 : 2015.01.22

초록

키워드

참고문헌

  1. Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53 https://doi.org/10.7314/APJCP.2014.15.3.1247
  2. D-C Liang1, L-Y Shih2, I-J Hung (2003). FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia, 17, 883-6 https://doi.org/10.1038/sj.leu.2402928
  3. Ishfaq M, Malik A, Faiz M, et al (2012). Molecular characterization of FLT3 mutations in acute leukemia patients. Asian Pac J Cancer Prev, 13, 4581-85 https://doi.org/10.7314/APJCP.2012.13.9.4581
  4. Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-9. https://doi.org/10.1182/blood.V98.6.1752
  5. Karabacak, BH, Erbey F, Bayram I, et al (2010). Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis. Asian Pac J Cancer Prev, 11, 923-7.
  6. Mead AJ, Gale RE, Hills RK, et al (2008) Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood, 112, 444-5. https://doi.org/10.1182/blood-2008-02-140392
  7. Renneville A, Abdelali RB, Chevret S, et al (2014). Clinical impact of gene mutations and lesions detected by SNParray karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 5, 916-32. https://doi.org/10.18632/oncotarget.1536
  8. Shahab S, Shamsi T, Ahmed N (2012). Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia. Asian Pac J Cancer Prev, 13, 4215-20. https://doi.org/10.7314/APJCP.2012.13.8.4215
  9. Su L, Gao SJ, Tan YH, Han W, Li W (2013). Associations Between Age, Cytogenetics, FLT3-ITD, and Marrow Leukemia Cells Identified by Flow Cytometry. Asian Pac J Cancer Prev, 14, 5341-4. https://doi.org/10.7314/APJCP.2013.14.9.5341
  10. Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3- activating mutations in 979 patients with acute myelogenous leukemia association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35 https://doi.org/10.1182/blood.V99.12.4326
  11. Weisberg E, Sattler M, Ray A, Griffin JD (2010) Drug resistance in mutant FLT3-positive AML. Oncogene, 29, 5120-34. https://doi.org/10.1038/onc.2010.273